FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DRREDDY

4,879.9
+34.35 (0.71%)
Updated 03:29 16/04 IST

DRREDDY Buy or Sell - FrontPage Forums

12 Users have submitted 13 trade ideas of Rs. 2,214,061.35 for DRREDDY
Disclaimer
100% Bullish
0% Bearish

DRREDDY Buy or Sell - Brokerage Reports

No. of reports in last year
19
No. of analysts
7
Average Consensus Forecast
5390.16
Consensus Potential
8.22%
See DRREDDY Share Price Targets >>

DRREDDY Ratings

Long term DRREDDY rating by FrontPage users
4.5/5 (11 Ratings)
Find answers to all your questions on live DRREDDY message board: Is DRREDDY buy or sell? Should I buy DRREDDY shares? Why are DRREDDY shares falling? Should I invest in DRREDDY stock?

  1. Home
  2. DRREDDY Forum

DRREDDY Share Price Discussion


Type
Buy
Instrument
DRREDDY
Entry Price
₹4,885.95
Price@Trade
₹4,885.95
Target Price
₹5,100
Stop Price
₹4,800
Valid Till
May 14, 2021 3:20 AM
Margin
₹488,595 approx for 100 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,908
Price@Trade
₹4,908
Target Price
₹4,950
Stop Price
₹4,890
Valid Till
Apr 15, 2022 3:20 AM
Margin
₹490,800 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹4,890
Net P&L
-₹1,800 (-0.37%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Stoploss Hit
Exit Price
₹4,890

Type
Buy
Instrument
DRREDDY APR21 5300 CE
Entry Price
₹50
Price@Trade
₹50
Target Price
₹80
Stop Price
₹45
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹6,250 approx for 125 Qty
Status
Validity Over
Exit Price
₹49.05
Net P&L
-₹118.75 (-1.9%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Validity Over
Exit Price
₹49.05
Net P&L
-₹118.75 (-1.9%)

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,920
Price@Trade
₹4,917.45
Target Price
₹5,000
Stop Price
₹4,910
Valid Till
Apr 26, 2021 3:20 AM
Margin
₹24,600 approx for 5 Qty
Status
Waiting for entry
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,922.9
Price@Trade
₹4,922.9
Target Price
₹5,100
Stop Price
₹4,800
Valid Till
May 14, 2021 3:20 AM
Margin
₹49,229 approx for 10 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,928.9
Price@Trade
₹4,928.9
Target Price
₹49,324
Stop Price
₹492
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹739,335 approx for 150 Qty
Status
Validity Over
Exit Price
₹4,888.55
Net P&L
-₹6,052.5 (-0.82%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Validity Over
Exit Price
₹4,888.55
Net P&L
-₹6,052.5 (-0.82%)
N
Reputation: 0 • Yesterday 7:30 AM

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,925
Price@Trade
₹4,917.85
Target Price
₹4,955
Stop Price
₹4,895
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹492,500 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹4,895
Net P&L
-₹3,000 (-0.61%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:47 AM

Update
Trade Entered
Entry Price
₹4,925
TrackerBot @trackerbot
Yesterday 8:32 AM

Update
Stoploss Hit
Exit Price
₹4,895

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,920
Price@Trade
₹4,919.1
Target Price
₹5,020
Stop Price
₹4,910
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹246,000 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹4,910
Net P&L
-₹500 (-0.2%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 7:27 AM

Update
Trade Entered
Entry Price
₹4,920
TrackerBot @trackerbot
Yesterday 7:32 AM

Update
Stoploss Hit
Exit Price
₹4,910

Type
Buy
Instrument
DRREDDY APR21 5000 CE
Entry Price
₹125.5
Price@Trade
₹125.5
Target Price
₹200
Stop Price
₹85
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹15,687.5 approx for 125 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,896.5
Price@Trade
₹4,895
Target Price
₹4,915
Stop Price
₹4,895
Valid Till
Apr 19, 2021 3:20 AM
Margin
₹4,896.5 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹4,895
Net P&L
-₹1.5 (-0.03%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 6:15 AM

Update
Trade Entered
Entry Price
₹4,896.5
TrackerBot @trackerbot
Yesterday 6:15 AM

Update
Stoploss Hit
Exit Price
₹4,895

Type
Buy
Instrument
DRREDDY APR21 5000 CE
Entry Price
₹126
Price@Trade
₹126
Target Price
₹320
Stop Price
₹0
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹31,500 approx for 250 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
DRREDDY APR21 5000 PE
Entry Price
₹227
Price@Trade
₹227
Target Price
₹250
Stop Price
₹210
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹28,375 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹210
Net P&L
-₹2,125 (-7.49%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 6:07 AM

Update
Stoploss Hit
Exit Price
₹210
G
Reputation: 0 • Yesterday 5:50 AM

Type
Buy
Instrument
DRREDDY APR21 4850 PE
Entry Price
₹136.8
Price@Trade
₹136.8
Target Price
₹160
Stop Price
₹120
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹17,100 approx for 125 Qty
Status
Stoploss Hit
Exit Price
₹120
Net P&L
-₹2,100 (-12.28%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 6:34 AM

Update
Stoploss Hit
Exit Price
₹120
Like
Reply

Type
Buy
Instrument
DRREDDY APR21 5300 CE
Entry Price
₹42.95
Price@Trade
₹42.95
Target Price
₹80
Stop Price
₹35
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹10,737.5 approx for 250 Qty
Status
Validity Over
Exit Price
₹49.05
Net P&L
+₹1,525 (+14.2%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:50 AM

Update
Validity Over
Exit Price
₹49.05
Net P&L
+₹1,525 (+14.2%)

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,891
Price@Trade
₹4,891
Target Price
₹5,101
Stop Price
₹4,850
Valid Till
Apr 19, 2021 3:20 AM
Margin
₹4,891 approx for 1 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,893
Price@Trade
₹4,895.9
Target Price
₹6,000
Stop Price
₹4,780
Valid Till
May 14, 2021 3:20 AM
Margin
₹978,600 approx for 200 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 5:16 AM

Update
Trade Entered
Entry Price
₹4,893

Type
Buy
Instrument
DRREDDY APR21 4900 CE
Entry Price
₹163.15
Price@Trade
₹163.15
Target Price
₹199
Stop Price
₹150  ₹160
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹20,393.75 approx for 125 Qty
Status
Stoploss Hit
Exit Price
160.0
Net P&L
-₹393.75 (-1.93%)
Like
Reply (2)
swap_vert
Trade
See all replies
Prasad @sspchundi
Yesterday 5:15 AM

Update
Stoploss Trailed
Price @ Update
₹166
Original SL
₹150
New SL
160.0
TrackerBot @trackerbot
Yesterday 5:24 AM

Update
Stoploss Hit
Exit Price
160.0
B
Reputation: 0 • Yesterday 5:10 AM

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,913
Price@Trade
₹4,899.8
Target Price
₹5,000
Stop Price
₹4,850
Valid Till
Apr 16, 2021 3:20 AM
Margin
₹491,300 approx for 100 Qty
Status
Exited
Exit Price
₹4,927.7
Net P&L
+₹1,470 (+0.3%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 6:34 AM

Update
Trade Entered
Entry Price
₹4,913
Bhaveek @bhaveek
Yesterday 8:19 AM

Update
Exited
Exit Price
₹4,927.7
Net P&L
+₹1,470 (+0.3%)
S
Reputation: 0 • Yesterday 5:10 AM

Type
Buy
Instrument
DRREDDY APR21 5050 CE
Entry Price
₹110
Price@Trade
₹110
Target Price
₹300
Stop Price
₹40
Valid Till
Apr 29, 2021 3:20 AM
Margin
₹275,000 approx for 2500 Qty
Status
Exited
Exit Price
₹120.9
Net P&L
+₹27,250 (+9.91%)
Like
Reply (1)
swap_vert
Trade
See all replies
Sid157 @sid157
Yesterday 7:55 AM

Update
Exited
Exit Price
₹120.9
Net P&L
+₹27,250 (+9.91%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    13-Apr-21Axis DirectBuy5,700
    10-Mar-21Nirmal BangBuy5,594
    30-Jan-21Prabhudas LilladherBuy5,406
    18-Jan-21Axis DirectBuy6,200
    12-Jan-21SharekhanBuy6,500
    DRREDDY Brokerage Price Target
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Apr 164863.849404815.24893.25
    Apr 154842.94875.0547854845.55
    Apr 135144.75144.74751.14777.3
    Apr 124775512046954996.95
    Apr 94692.947944691.254760.3
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹4,557.95
    30 Day Moving Average₹4,526.44
    50 Day Moving Average₹4,571.59
    100 Day Moving Average₹4,810.11
    200 Day Moving Average₹4,684.2
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY - Recent News

    keyboard_arrow_down
    NewsBot
    Mar 5 9:03 AM
    Buy Dr Reddy’s Laboratories: Target Of Rs 6500: Sharekhan
    Moneycontrol
    NewsBot
    Feb 22 6:33 AM
    Dr Reddy's Launches Stomach, Esophagus Problems Treatment Drug In The US
    Moneycontrol
    NewsBot
    Feb 19 2:38 AM
    Dr Reddy's Begins Process To Obtain Emergency Use Authorisation For Sputnik V
    Moneycontrol
    NewsBot
    Feb 18 4:24 AM
    Dr Reddy's Launches Fluphenazine Hydrochloride Tablets In US
    Moneycontrol
    NewsBot
    Feb 8 9:43 AM
    Buy Dr. Reddy's Laboratories; Target Of Rs 5406: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Feb 7 8:33 AM
    Will Dr Reddy's Be Able To Reap The Benefit Of Sputnik V COVID-19 Vaccine?
    Moneycontrol
    NewsBot
    Feb 5 8:58 AM
    Buy Dr Reddy’s Laboratories; Target Of Rs 5525: ICICI Direct
    Moneycontrol
    NewsBot
    Feb 4 10:53 AM
    Neutral Dr Reddy’s Labs; Target Of Rs 5070: Motilal Oswal
    Moneycontrol
    NewsBot
    Feb 2 5:18 AM
    NewsBot
    Feb 1 2:08 AM
    Budget 2021 | Rs 35,000 Crore Allotment For COVID-19 Vaccination Brings Cheers To Vaccine Makers
    Moneycontrol
  • DRREDDY - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020